GRI Bio (NASDAQ: GRI) Participates in Virtual Investor "What This Means" Segment
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor "What This Means" Segment
Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF)
GRI Bio首席执行官Marc Hertz博士强调了他们正在进行的特发性肺纤维化（IPF）2a期生物标志物研究中期数据的重要性
LA JOLLA, CA, July 11, 2024 — GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio," "we," "our," or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the release of a Virtual Investor "What This Means" segment.
加利福尼亚州拉霍亚，2024年7月11日——GRI Bio, Inc.（纳斯达克股票代码：GRI）（“GRI Bio”、“我们” 或 “公司”）是一家推进用于治疗炎症、纤维化和自身免疫性疾病的自然杀手t（NKT）细胞调节剂创新产品线的生物技术公司，今天宣布发布虚拟投资者 “这意味着什么” 板块。
As part of this "What This Means" segment, Marc Hertz, PhD, Chief Executive Officer of GRI Bio discusses the interim data and what this means for its ongoing IPF program, GRI-0621. Watch the "What This Means" video here.
作为 “这意味着什么” 部分的一部分，GRI Bio首席执行官马克·赫兹博士讨论了中期数据以及这对其正在进行的IPF计划 GRI-0621 意味着什么。在此处观看 “这意味着什么” 视频。
The Virtual Investor "What This Means" segment featuring GRI Bio is now available here. Additional videos from the "What This Means" series are available on demand at .
以GRI Bio为主题的虚拟投资者 “这意味着什么” 栏目现已在此处提供。“这意味着什么” 系列的其他视频可在以下网址点播。
About GRI Bio, Inc.
关于 GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio's therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio's lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
GRI Bio是一家临床阶段的生物制药公司，致力于从根本上改变炎症、纤维化和自身免疫性疾病的治疗方式。GRI Bio的疗法旨在靶向NKT细胞的活性，NKT细胞是炎症级联早期的关键调节剂，以中断疾病进展并恢复免疫系统的动态平衡。NKT 细胞是与生俱来的 T 细胞，共有 NK 和 T 细胞的特性，是先天免疫反应和适应性免疫反应之间的功能纽带。1 型不变性 (inKT) 细胞在传播炎症和纤维化适应症中观察到的损伤、炎症反应和纤维化方面起着至关重要的作用。GRI Bio的主要项目 GRI-0621 是InKT细胞活性的抑制剂，正在开发为一种新的口服疗法，用于治疗特发性肺纤维化，这是一种严重的疾病，其需求尚未得到满足。该公司还在开发用于治疗系统性红斑狼疮的新型2型NKT激动剂产品线。此外，GRI Bio拥有超过500种专有化合物的库，有能力为不断增长的管道提供燃料。
Investor Contact:
投资者联系人：
JTC Team, LLC
Jenene Thomas
(833) 475-8247
GRI@jtcir.com
JTC Team, LLC
珍妮·托马斯
(833) 475-8247
GRI@jtcir.com
